Hikma subsidiary receives FDA approval for Temozolomide capsules

Hikma Pharmaceuticals’ fully-owned subsidiary West-Ward Pharmaceuticals has received approval from the US Food and Drug Administration for its abbreviated new drug application for Temozolomide capsules.

Temozolomide is a chemotherapy agent used to treat a severe form of brain cancer. According to IMS Health, a global information and technology services company for the healthcare industry, total US sales of Temozolomide capsules were around $200m for the 12 months ending January 2016.

Chairman and chief executive officer Said Darwazah said: “We are very pleased to announce our first approval from the Columbus portfolio (formerly Roxane Laboratories) since we closed the transaction on 29 February 2016.

“West-Ward has an excellent pipeline of differentiated products and proven R&D, supply chain and operational capabilities that we expect will drive accelerated and sustainable future growth."

At 1236 GMT, Hikma shares were up 2.4% to 1,940p.